Activity of ceftolozane/tazobactam against surveillance and 'problem' Enterobacteriaceae, Pseudomonas Aeruginosa and non-fermenters from the British Isles

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 8, 2017, Pages 2278-2289

  Livermore, D M ^a,b,b   Mushtaq, Shazad ^a   Meunier, Daniele ^a   Hopkins, Katie L ^a   Hill, Robert ^a   Adkin, Rachael ^a   Chaudhry, Aiysha ^a   Pike, Rachel ^a   Staves, Peter ^a   Woodford, Neil ^a   Allen, M ^b   Brown, D F G ^b   Longshaw, C ^b   MacGowan, A P G ^b  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN; AMPICILLIN; BETA LACTAMASE AMPC; CARBENICILLIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTOLOZANE; CIPROFLOXACIN; CLAVULANIC ACID; COLISTIN; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; MEROPENEM; METALLO BETA LACTAMASE; PIPERACILLIN PLUS TAZOBACTAM; TAZOBACTAM; TEMOCILLIN; TIGECYCLINE; TOBRAMYCIN; ANTIINFECTIVE AGENT; BETA LACTAMASE INHIBITOR; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID;

AGAR DILUTION; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; BURKHOLDERIA; DRUG MECHANISM; ENTEROBACTERIACEAE; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; PSEUDOMONAS AERUGINOSA; STENOTROPHOMONAS MALTOPHILIA; UNITED KINGDOM; UPREGULATION; ANALOGS AND DERIVATIVES; DRUG EFFECTS; EPIDEMIOLOGICAL MONITORING; GENETICS; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; POLYMERASE CHAIN REACTION;

ANTI-INFECTIVE AGENTS; BETA-LACTAMASE INHIBITORS; CEPHALOSPORINS; EPIDEMIOLOGICAL MONITORING; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; POLYMERASE CHAIN REACTION; UNITED KINGDOM;

EID: 85027156348     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkx136     Document Type: Article

References (35)

1. Sucher AJ, Chahine EB, Cogan P et al. Ceftolozane/tazobactam: a new cephalosporin and β-lactamase inhibitor combination. Ann Pharmacother 2015; 49: 1046-56
2. Livermore DM, Mushtaq S, Ge Y et al. Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates. Int J Antimicrob Agents 2009; 34: 402-6
3. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002; 34: 634-40
4. Reynolds R, Hope R, Williams L; BSAC Working Parties on Resistance Surveillance. Survey, laboratory and statistical methods for the BSAC Resistance Surveillance Programmes. J Antimicrob Chemother 2008; 62 Suppl 2: ii15-28
5. A guide to sensitivity testing. Report of the Working Party on Antibiotic Sensitivity Testing of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 1991; 27 Suppl D: 1-50
6. Livermore DM, Winstanley TG, Shannon KP. Interpretative reading: recognizing the unusual and inferring resistance mechanisms from resistance phenotypes. J Antimicrob Chemother 2001; 48 Suppl 1: 87-102
7. AkovaM, Yang Y, LivermoreDM. Interactions of tazobactam and clavulanate with inducibly-and constitutively-expressed Class I β-lactamases. J Antimicrob Chemother 1990; 25: 199-208
8. Normark S, Lindquist S, Lindberg F. Chromosomal β-lactam resistance in enterobacteria. Scand J Infect Dis Suppl 1986; 49: 38-45
9. Poirel L, Guibert M, Girlich D et al. Cloning, sequence analyses, expression, and distribution of ampC-ampR from Morganella morganii clinical isolates. Antimicrob Agents Chemother 1999; 43: 769-76
10. Doumith M, Ellington MJ, Livermore DM et al. Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK. J Antimicrob Chemother 2009; 63: 659-67
11. Babouee Flury B, Ellington MJ, Hopkins KL et al. Association of novel nonsynonymous single nucleotide polymorphisms in ampD with cephalosporin resistance and phylogenetic variations in ampC, ampR, ompF, and ompC in Enterobacter cloacae isolates that are highly resistant to carbapenems. Antimicrob Agents Chemother 2016; 60: 2383-90
12. Poirel L, Héritier C, Tolún V et al. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother 2004; 48: 15-22
13. Livermore DM, Yang YJ. β-Lactamase lability and inducer power of newer β-lactamantibiotics in relation to their activity against β-lactamase-inducibilitymutants of Pseudomonas aeruginosa. J InfectDis 1987; 155: 775-82
14. Papp-Wallace KM, Bonomo RA. New β-lactamase inhibitors in the clinic. Infect Dis Clin NorthAm2016; 30: 441-64
15. Livermore DM, Mushtaq S, Ge Y. Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus β-lactamase-producing Enterobacteriaceae. JAntimicrobChemother 2010; 65: 1972-4
16. Farrell DJ, SaderHS, Mendes RE et al. Activity of ceftolozane/tazobactam tested against organisms from urinary tract pathogens collected from 41 medical centers in Europe, Turkey and Israel (2014). In: Abstracts of the Twenty-sixth European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, The Netherlands, 2016. Abstract P0337. ESCMID, Basel, Switzerland
17. Papp-Wallace KM, Bethel CR, Distler AM et al. Inhibitor resistance in the KPC-2 β-lactamase, a preeminent property of this class A β-lactamase. Antimicrob Agents Chemother 2010; 54: 890-7
18. Williams RJ, Livermore DM, Lindridge MA et al. Mechanisms of β-lactam resistance in British isolates of Pseudomonas aeruginosa. J Med Microbiol 1984; 17: 283-93
19. Chen HY, Yuan M, Livermore DM. Mechanisms of resistance to β-lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993. JMedMicrobiol 1995; 43: 300-9
20. Cavallo JD, Leblanc F, Fabre R et al. Survey of the antibiotic sensitivity of Pseudomonas aeruginosa in France and the distribution of β-lactamresistance mechanisms: the GERPB 1999 study. Pathol Biol (Paris) 2001; 49: 534-9
21. Bonfiglio G, Laksai Y, Franchino L et al. Mechanisms of β-lactam resistance amongst Pseudomonas aeruginosa isolated in an Italian survey. JAntimicrobChemother 1998; 42: 697-702
22. Cabot G, Ocampo-Sosa AA, Tubau F et al. Overexpression of AmpCand efflux pumps in Pseudomonas aeruginosa isolates frombloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. Antimicrob Agents Chemother 2011; 55: 1906-11
23. Al-Agamy MH, Shibl AM, Tawfik AF et al. Extended-spectrum and metallo-β-lactamases among ceftazidime-resistant Pseudomonas aeruginosa in Riyadh, Saudi Arabia. JChemother 2012; 24: 97-100
24. Strateva T, Ouzounova-Raykova V, Markova B et al. Widespread detection of VEB-1-type extended-spectrum β-lactamases among nosocomial ceftazidime-resistant Pseudomonas aeruginosa isolates in Sofia, Bulgaria. JChemother 2007; 19: 140-5
25. Edelstein MV, Skleenova EN, Shevchenko OV et al. Spread of extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study. Lancet Infect Dis 2013; 13: 867-76
26. Cabot G, Bruchmann S, Mulet X et al. Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. Antimicrob Agents Chemother 2014; 58: 3091-9
27. Bonfiglio G, Livermore DM. Effect of media composition on the susceptibility of Xanthomonas maltophilia to β-lactam antibiotics. J Antimicrob Chemother 1991; 28: 837-42
28. Bonacorsi S, Fitoussi F, Lhopital S et al. Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combinationwith tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 1999; 43: 213-7
29. Chang YT, Lin CY, Chen YH et al. Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistancemechanisms and therapeutic options. FrontMicrobiol 2015; 6: 893
30. Sousa-Dominguez A, Perez-Rodríguez MT, Nodar A et al. Successful treatment of MDR Pseudomonas aeruginosa skin and soft-tissue infection with ceftolozane/tazobactam. J Antimicrob Chemother 2016; 72: 1262-3
31. Castón JJ, De la Torre Á, Ruiz-Camps I et al. Salvage therapy with ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections. Antimicrob Agents Chemother 2017; 61: e02136-16
32. Hernández-Tejedor A, Merino-Vega CD, Martín-Vivas A et al. Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam. Infection 2017; 45: 115-7
33. Vickery SB, McClain D, Wargo KA. Successful use of ceftolozanetazobactam to treat a pulmonary exacerbation of cystic fibrosis caused by multidrug-resistant Pseudomonas aeruginosa. Pharmacotherapy 2016; 36: e154-9
34. Gelfand MS, Cleveland KO. Ceftolozane/tazobactam therapy of respiratory infections due to multidrug-resistant Pseudomonas aeruginosa. Clin Infect Dis 2015; 61: 853-5
35. Berrazeg M, Jeannot K, Ntsogo Enguéné VY et al. Mutations in β-lactamase AmpC increase resistance of Pseudomonas aeruginosa isolates to antipseudomonal cephalosporins. Antimicrob Agents Chemother 2015; 59: 6248-55